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PERSPECTIVES IN CLINICAL NEPHROLOGY
Growth hormone and calcitriol as modifiers of bone formation in
renal osteodystrophy
Growth retardation is a major consequence of renal failure in
children [1, 2]. Evidence that bone age lags behind chronological
age appears relatively early in the course of progressive renal
disease, and growth retardation becomes a prominent clinical
feature in most pediatric patients with advanced renal failure and
in those undergoing regular dialysis [3, 4]. Impaired linear growth
persists despite ongoing renal replacement therapy with either
hemodialysis or peritoneal dialysis, and improvements in linear
growth after successful renal transplantation usually fail to fully
correct pre-existing growth retardation [5]. Accordingly, there is
considerable interest in therapeutic interventions that can prevent
or reverse the retardation of growth in children with end-stage
renal disease.
Several factors are thought to contribute to impaired skeletal
growth in pediatric patients with renal disease: anemia, protein
and calorie malnutrition, acidosis, calcitriol deficiency, renal
osteodystrophy and tissue resistance to the actions of growth
hormone, but the relative importance of each remains uncertain
[61. Despite these considerations, the introduction of recombinant
human growth hormone (rhGH) for the treatment of growth
retardation in children with chronic renal failure holds consider-
able promise [7—9]. Growth hormone has potent effects, however,
on bone and mineral metabolism [10-43], and its use can be
expected to influence certain manifestations of renal osteodystro-
phy and their management. Because many pediatric patients
receive calcitriol, 1,25-dihydroxyvitamin D or other vitamin D
derivatives as an integral part of their overall therapeutic regimen
[7—9, 14, 15], the potential for complex interactions between these
two hormonal regulators of bone metabolism should be recog-
nized. In the discussion that follows, the separate actions of
growth hormone and calcitriol on bone and cartilage are dis-
cussed, and the interplay between these two agents on the manage-
ment of pediatric patients with renal bone disease is considered.
Assessing bone metabolism in the developing skeleton
It is important to recognize that, unlike adults, bone is formed
by two distinct mechanisms during skeletal development in chil-
dren [16]. In addition to bone laid down during the process of
skeletal remodeling, skeletal accretion and longitudinal growth
also occur through the process of endochondral bone formation in
the immature skeleton. The modeling of bones is achieved both by
appositional growth along periosteal surfaces and by the primary
calcification of cartilage adjacent to the growth plate at the ends
of long bones. The remodeling of existing mineralized tissue in
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cortical and cancellous bone and the modeling of new bone are
each ongoing processes in growing children. It is likely that these
two processes are controlled by different sets of hormonal medi-
ators and/or that the tissue specific actions of selected hormones
differ in chondrocytes, which regulate endochondral bone forma-
tion during linear growth, and osteoblasts, which regulate bone
formation during skeletal remodeling throughout life.
In this context, the meaning of various non-invasive indices of
bone metabolism that are extensively used for the assessment of
adults with metabolic bone disease, such as the serum levels
of alkaline phosphatase, osteocalcin, and tartrate-resistant acid
phosphatase, may differ substantially in children since none of
these biochemical markers is specific for either the process of
bone modeling or skeletal remodeling. Thus, biochemical findings
in children due to changes in the level of cellular activity in one of
these compartments may not accurately reflect activity in the
other compartment.
Actions of calcitriol
Calcitriol, or 1,25-dihydroxyvitamin D, is the most potent
metabolite of vitamin D, and it accounts for most, if not all, of the
diverse biologic actions of vitamin D. Because calcitriol is synthe-
sized primarily in the mitochondria of proximal renal tubular
epithelial cells [17], alterations in renal calcitriol production and
vitamin D metabolism are a hallmark of renal failure. Serum
calcitriol levels decline progressively with advancing renal insuf-
ficiency, and values are markedly reduced in patients with end-
stage renal disease [18, 19]. Indeed, modest reductions in serum
calcitriol levels have been documented in children and adults with
glomerular filtration rates in the range of 70 to 80 ml/min/1.73 m2
[20, 21].
Shortly after it became available for clinical use, Chesney et al
reported that calcitriol therapy improved linear growth when
given to children with advanced renal failure [22]. Consequently,
calcitriol, or its structurally related precursor la-hydroxyvitamin
D [15], are often prescribed for the prevention and management
of growth retardation in children with renal disease, and they are
currently recommended for this purpose in nearly all pediatric
patients with advanced renal failure [4]. It should be noted,
however, that the number of patients evaluated in this initial
report was quite small [22], and a subsequent larger clinical trial
failed to demonstrate substantial differences between calcitriol
and dihydrotachysterol (DHT) in the rate of linear growth in
children with stable chronic renal failure [23]. The widely held
view that calcitriol administration is essential for the maintenance
of linear growth and development in children and adolescents
with renal failure warrants careful reconsideration, particularly in
view of recent data about the changing pattern of renal bone
disease in those undergoing regular dialysis (vide infra), [24—27]. It
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is possible that the previously reported beneficial effect of 1,25-
dihydroxyvitamin D on linear growth in children is limited to
those with severe secondary hyperparathyroidism but does not
reflect a more general growth-promoting action of the sterol.
In this regard, calcitriol has important direct as well as indirect
effects on skeletal metabolism. Calcitriol is a potent mediator of
intestinal calcium transport, and impaired renal 1,25-dihydroxyvi-
tamin D production contributes to the overall decline in intestinal
calcium absorption in patients with chronic renal failure [28]. The
mobilization of calcium and phosphorus from bone is also im-
paired in the absence of 1,25-dihydroxyvitamin D [29]. Because
serum calcium and phosphorus levels must be adequately main-
tained to mineralize newly formed bone collagen, persistently low
serum calcium levels due to diminished 1,25-dihydroxyvitamin D
synthesis can slow skeletal growth and development. Thus, histo-
logic evidence of osteomalacia was quite common in pediatric
patients with renal osteodystrophy before the widespread avail-
ability of active vitamin D sterols [30, 31]. Both the process of
endochondral bone formation, which occurs predominantly at the
ends of long bones, and the mineralization of newly formed bone
collagen, which occurs at sites of active skeletal remodeling in
cortical and cancellous bone, are adversely affected. Fortunately,
osteomalacia due to calcitriol and/or mineral deficiency is seen
infrequently nowadays; when present, it is often due to other
causes such as aluminum intoxication [32, 33].
Impaired renal calcitriol production can also affect bone me-
tabolism due to its role as a regulator of parathyroid hormone
(PTH) synthesis and secretion [34, 35]. Years ago, Mehis docu-
mented specific changes in growth plate cartilage due to severe
secondary hyperparathyroidism in children with chronic renal
failure, and and found that involvement of the growth plate of
long bones in pediatric patients with osteitis fibrosa may lead to
the development of slipped epiphyses, bone deformities and
impaired linear growth [3].
In addition to fibrotic changes of the growth plate in children
with secondary hyperparathyroidism, PTH enhances both osteo-
blastic and osteoclastic activity in mineralized bone, and it may
also promote osteoclast differentiation [36—38]. Available evi-
dence indicates that the level of PTH in serum is the major
determinant of cancellous bone formation and turnover both in
adults and in children with chronic renal failure [33, 39, 40]. As
such, variations in serum 1,25-dihydroxyvitamin D levels resulting
from changes in endogenous calcitriol synthesis or from different
schedules of oral or parenteral calcitriol administration may alter
bone metabolism and skeletal growth through PTH-dependent
mechanisms.
Recent data also indicate that expression of the receptor for
PTH and PTH related peptide (PTHrP), and the production of
PTHrP itself, play a critical role in normal endochondral bone
development [41]. Mice in which the gene for PTHrP has been
homozygously deleted die shortly after birth or fail to survive
intrauterine life, and they demonstrate marked abnormalities in
skeletal development [42]. Epiphyseal growth plates are markedly
foreshortened, and the primary calcification of epiphyseal carti-
lage occurs prematurely. There is also evidence of a generalized
over-mineralization of the skeleton. Such findings indicate that
PTH and PTHrP, and their receptor, play a pivotal role in normal
skeletal development, and it is possible that disturbances in this
regulatory pathway can alter cartilage development and epiphy-
seal growth in selected clinical disorders such as chronic renal
failure. In this regard, mRNA levels for the PTH/PTHrP receptor
are reduced in the kidney of experimental animals with renal
failure [431, but the role of alterations in calcitriol metabolism as
a regulator of osteoblastic and chondrocytic PTH/PTHrP receptor
expression in chronic renal failure remains to be determined.
In addition to these indirect actions of calcitriol on bone,
1,25-dihydroxyvitamin D has important direct effects on both
osteoblasts and chondrocytes [44]. In vitro studies have demon-
strated that 1,25-dihydroxyvitamin D inhibits the rate of cell
proliferation both in chondrocytes and in osteoblast-like cells,
whereas it serves as a key regulator of cell differentiation in bone
and in other tissues. Also, 1,25-dihydroxyvitamin D reduces
collagen synthesis by osteoblasts, and neither growth hormone nor
insulin-like growth factor I (IGF-I) offsets the inhibitory actions of
calcitriol on collagen synthesis in vitro [45—48]. Recent data
obtained in pediatric patients with secondary hyperparathyroid-
ism undergoing intermittent calcitriol therapy are consistent with
a direct in vivo inhibitory action of 1,25-dihydroxyvitamin D on
osteoblastic activity in cancellous bone [251.
Actions of growth hormone
There is considerable evidence that disturbances in growth
hormone metabolism contribute to delayed skeletal development
in pediatric patients with chronic renal disease [49, 50]. Although
the serum levels of growth hormone (GH) are normal or in-
creased [51], various measures of the tissue response to GH are
diminished in patients with chronic renal failure [52, 53]. Changes
in receptor expression and in post-receptor events may each
contribute to these findings. Since the actions of GH are mediated
through insulin-like growth factor I (IGF-I), the various IGF
binding proteins, some of which are inhibitory for IGF-I, provide
an additional mechanism by which tissue-specific actions of GH or
attenuated responses to GH may be mediated in chronic renal
failure [49, 50]. The physiology of GH and the insulin-like growth
factors has recently been reviewed in detail [54].
The availability of recombinant human growth hormone
(rhGH) has had a profound effect on the management of growth
retardation in pediatric patients with chronic renal failure [7, 9,
14, 55—58]. Several studies have documented improvements in
growth velocity and in other anthropomorphic parameters of
development in children during rhGH therapy. Although most
available data have been obtained in patients with stable chronic
renal failure [14], favorable responses to rhGH have also been
documented in children undergoing regular dialysis and in those
who have undergone successful renal transplantation [8, 57, 58].
The clinical response to rhGH differs substantially, however,
among these three groups [57]. Increases in linear growth are less
in children receiving either hemodialysis or peritoneal dialysis
than in patients with stable chronic renal failure [57]. Moreover,
height velocity decreases by nearly 50% during the second year of
rhGH treatment in pre-pubertal children undergoing regular
dialysis, suggesting that the effect of rhGH on linear growth
becomes attenuated with continued therapy [59]. The explanation
for these observations remains uncertain, but down-regulation of
receptors for GH and IGF-I, formation of antibodies to rhGH and
non-compliance are important considerations that warrant further
evaluation [591.
In addition to its effects on linear growth, GH has diverse effects
on bone and mineral metabolism, some of which are manifested in
patients with clinical conditions of excess GH secretion or GH
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Fig. 1. Actions of growth hormone in growth
plate cartilage (adapted from [79]).
deficiency [10—13]. Patients with acromegaly exhibit high rates of
skeletal remodeling as judged by increases in the serum levels of
alkaline phosphatase and osteocalcin [12]. Intestinal calcium
absorption is enhanced, possibly due to GH-mediated increases in
intestinal 9 kD-calbindin [11, 60—62]. Biopsies of the iliac crest
demonstrate increased osteoblastic activity and high rates of bone
formation [63]. Bone mass is also greater than normal [64];
whether this finding reflects changes in the intrinsic mineral
density of cancellous bone or increases in the dimensions of bones
remains to be determined.
In contrast to these findings, patients with GH deficiency have
diminished bone mass, and serum osteocalcin levels are low [65,
66]; the latter finding is consistent with a generalized decrease in
osteoblastic activity. Moreover, the administration of rhGH to
adult patients with GH deficiency raises the rate of bone forma-
tion, and the excretion of deoxypyridinoline in the urine increases,
presumably the result of enhanced skeletal remodeling during
rhGH therapy [67]. Deoxypyridinoline is a stable degradation
product of type I collagen derived from sites of intermolecular
cross linkage, and it is considered to be a reliable index of collagen
breakdown during the process of bone resorption.
Additional findings during rhGH administration in normal
volunteers include increases in calcium excretion in the urine and
a rise in serum phosphorus levels; serum 1,25(OH)2D5, osteocal-
cm and IGF-I levels may also increase [62, 68]. Although hyper-
calciuria has been reported in rats with renal failure given rhGH
together with calcitriol [69], a rise in renal calcium excretion was
not observed during rhGH therapy in children with stable chronic
renal failure [70, 71]. Growth hormone enhances the renal tubular
reabsorption of phosphorus, thereby raising serum phosphorus
levels, and this change can indirectly modify the renal production
of 1,25-dihydroxyvitamin D [72]. Direct effects of GH on renal
la-hydroxylase activity may also contribute to alterations in
vitamin D metabolism. Growth hormone appears to mediate the
increase in renal 1,25-dihydroxyvitamin D production during
phosphate restriction, but IGF-I is equally effective in maintaining
this response [73, 74].
In longer-term studies of adults with GH deficiency, serum
calcium and phosphorus levels rose whereas serum PTH levels
declined during treatment with rhGH [72]. Similar modest reduc-
tions in serum PTH levels have been reported in children with
normal renal function given rhGH for the treatment of cortico-
steroid-induced osteoporosis [75]. Whether variations in GH
secretion and/or IGF-I production also affect renal vitamin D
metabolism and serum calcitriol levels in patients with chronic
renal failure remains uncertain.
Direct actions of GH in the skeleton include effects on bone
and on cartilage (Fig. 1) [76, 77]. Overall, growth hormone is
critical for post-natal skeletal growth, and it induces endochondral
ossification by acting directly on cells within cartilaginous growth
plates [78]. A proliferative response to GH has been well-
documented in chondroprogenitor cells from the epiphyseal
growth plate in vivo and in vitro, and GH is a major regulator of
cartilage growth [79]. Growth hormone stimulates the synthesis of
IGF-I locally within growth plate cartilage [79], and both GH and
IGF-I enhance the differentiation of prechondrocytes to mature
chondrocytes. In epiphyseal cartilage, IGF-I acts primarily in a
paracrine manner to enhance chondrocyte proliferation, but other
cytokines and growth factors also play a role [77, 80]. After
puberty, the role of IGF-I as a mediator of the response to GH is
less clear because most of the actions of growth hormone in
cartilage have been characterized in studies of young growing
animals.
In bone, GH promotes enhances the proliferation of osteoblasts
and increases new bone formation [78]. Alkaline phosphatase
activity and osteocalcin production, biochemical indices of differ-
entiated osteoblastic function, are markedly enhanced by growth
hormone in osteoblast-like cells [72, 81]. As in cartilage, the
actions of GH on osteoblasts appear to be mediated through
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Fig. 2. The spectrum of renal osteodystrophy in patients treated with daily oral calcitriol.
IGF-I [82], and both GH and IGF-I stimulate cell replication and
collagen synthesis.
The bone trophic actions of GH differ markedly from the
inhibitory actions of 1,25-dihydroxyvitamin D on osteoblasts [48].
Cell proliferation in vitro is inhibited by 1,25-dihydroxyvitamin D
in chondrocytes and in osteoblast-like cells, and neither GH nor
IGF-I is capable of overcoming this inhibitory effect [45—48].
Also, 1,25-dihydroxyvitamin D reduces collagen synthesis by
osteoblasts [44]. Since growth hormone and calcitriol have widely
divergent effects on bone formation, the concurrent therapeutic
use of these two agents in patients with chronic renal failure is
likely to substantially affect bone metabolism. As such, available
information about the relationship between the serum levels of
PTH and the rates of bone formation and turnover in pediatric
patients with renal osteodystrophy may not apply to those given
rhGH [33]. There are currently no data that address this issue in
children with chronic renal failure.
The spectrum of renal osteodystrophy
Bone disease is a nearly universal complication of chronic renal
failure, and it encompasses a spectrum of skeletal disorders
ranging from high-turnover to low-turnover lesions (Fig. 2) [83].
According to this schema, the subtypes of renal bone disease
represent different histopathologic manifestations along a contin-
uum with PITT, vitamin D and calcium, and in some circum-
stances aluminum, serving as major regulators of osteoblastic
activity and bone formation. Several recent studies indicate that
the prevalence of low-turnover compared to high-turnover lesions
of renal osteodystrophy has increased substantially in the adult
and pediatric dialysis population [24—27, 84, 85]. These findings
are in marked contrast to results reported during the 1970's and
1980's when high-turnover lesions were the predominant skeletal
disorder in patients with chronic renal failure, and they under-
score the evolving pattern of renal bone disease [86, 87].
Several factors that may account for the increased prevalence of
adynamic renal osteodystrophy have been identified including the
widespread use of large doses of calcium carbonate as a phos-
phate-binding agent, intense therapy with vitamin D sterols and
treatment with peritoneal dialysis [25, 88, 89]. Additional risk
factors for the development of the adynamic lesion include
diabetes, increasing age, parathyroidectomy, previous renal trans-
plantation and/or corticosteroid therapy [24].
Biochemical markers of renal osteodystrophy
Because it is impractical to obtain repeated bone biopsies in
most patients other than in the research setting, biochemical
measures such as serum PTH, alkaline phosphatase and calcium
levels are widely used as surrogate therapeutic endpoints to
monitor the progression of renal bone disease and its response to
treatment [33, 39, 40, 83, 90, 91]. The value of these biochemical
indices relates to their ability to accurately predict the type of
renal bone disease as documented by histomorphometric assess-
ments.
Among the currently available non-invasive markers of bone
and mineral metabolism, serum PTH measurements using assays
for the intact ito 84 amino acid peptide best distinguish between
patients with high-turnover or low-turnover skeletal lesions of
renal osteodystrophy (Fig. 3). The immunoradiometric assay
(IRMA) does not measure mid-region or carboxy-terminal frag-
ments of PTH that are retained in the serum of patients with
chronic renal failure [92]; thus, values more reliably identify those
with specific histologic subtypes of renal osteodystrophy in chil-
dren receiving daily doses of oral calcitriol, particularly when used
together with concurrent measurements of the serum calcium
level [33, 40, 93, 94]. None of the data currently available have
been obtained, however, in children receiving rhGH, and the
future utility of non-invasive biochemical markers as predictors of
bone formation and turnover in pediatric patients with renal bone
disease during treatment with rhGH will require additional eval-
uation. Indeed, many pediatric patients given rhGH demonstrate
marked increases in serum alkaline phosphatase and osteocalcin
levels [9, 55], and hypercalcemia develops in some patients.
The potential for discrepancies among values for serum PTH
and alkaline phosphatase and the rate of bone formation is
illustrated in three patients with chronic renal failure receiving
daily calcitriol therapy, two of whom were also treated with with
rhGH (Table 1). In Example #1, the serum PTH level is only
modestly elevated, a value consistent with the measured rate of
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Fig. 3. Serum PTH levels according to the type of renal bone disease in
children undergoing CAPD/CCPD. Abbreviations are: OF, osteitis fibrosa;
M, mild lesion of secondary hyperparathyroidism; N, normal bone forma-
tion; and AP, adynamic, or aplastic, lesion. The enclosed area represents
the range of normal values for serum PTH levels. (From reference [33];
used with permission.)
bone formation which falls within the lower portion of the normal
range and which approaches values seen in patients with the
adynamic lesion [331. The serum alkaline phosphatase level is
markedly elevated, however, and this biochemical finding would
commonly be taken as evidence of overt secondary hyperparathy-
roidism if bone biopsy data to the contrary were not available in
this patient treated with rhGH. This combination of biochemical
findings suggests that chondrocytes within the growth plate rather
than osteoblasts within cancellous bone represent the source of
the alkaline phosphatase activity.
In Example #2, the high serum levels of PTH and alkaline
phosphatase are consistent with the elevated rate of bone forma-
tion in this patient with secondary hyperparathyoidism who was
not given rhGH. In contrast, Example #3, who received long-term
growth hormone therapy, had a high rate of bone formation
despite only modestly elevated serum alkaline phosphatase and
PTH levels. The substantial discrepancy between the biochemical
and histologic findings in this case suggests that rhGH can directly
influence osteoblastic activity in remodeling bone.
Such biochemical findings underscore the potential difficulty in
monitoring the evolution of renal bone disease and its response to
treatment in patients with renal disease who are also given rhGH.
Since PTH is considered to be the primary determinant of bone
formation during the process of skeletal remodeling both in adults
and in children with renal osteodystrophy, the influence of
treatment with rhGH on this relationship warrants careful re-
evaluation. All previous studies of renal osteodystrophy in chil-
dren have been done in patients who were not receiving growth
hormone. Moreover, because growth hormone can influence bone
formation and turnover by PTH-independent mechanisms, con-
siderable additional information will be required to characterize
the impact of this powerful bone trophic agent on the skeletal
manifestations of renal osteodystrophy in pediatric patients.
Therapeutic approach to renal osteodystrophy
The primary goals of treatment in patients with renal osteodys-
trophy are to return bone formation toward normal and to
maintain serum PTH levels in a range that corresponds to a
normal rate of skeletal remodeling [83]. Oral calcitriol therapy or
other vitamin D derivatives have been used for many years to treat
secondary hyperparathyroidism in patients undergoing regular
Example
#1 #2 #3
Age years 13 9 10
rhGH Rx months 68 — 81
1,25-D p.g/day 0.75 0.25 0.25
Ca mg/dl 8.8 8.9 9.0
P04 mg/dl 3.7 5.9 5.1
Alk. P'Tase lU/liter 1565 1055 323
PTH pg/mi 206 1214 192
BFR jsm2/mm2/day 110 1789 1130
dialysis [4, 15, 95, 96]. Many patients respond favorably to daily
oral calcitriol therapy, but those with more advanced secondary
hyperparathyroidism often fail to show biochemical, radiological
and/or histologic improvement [97, 98].
In 1984, Slatopolsky et al demonstrated that the intravenous
administration of calcitriol thrice weekly could markedly lower
serum PTH levels in adult hemodialysis patients with mild to
moderate secondary hyperparathyroidism [99]. Similar findings
were subsequently reported using large intermittent doses of oral
calcitriol given two or three times each week [100—102]. Thus,
intermittent schedules of calcitriol administration, either orally or
intravenously, have become widely used for the treatment and
prevention of secondary hyperparathyroidism in those undergoing
regular dialysis.
Unfortunately, only limited information is available about the
histologic response of bone to treatment with intermittent doses
of calcitriol [103]. Marked reductions in bone formation have
been documented after thrice weekly doses of intravenous calcit-
riol in adult patients with advanced secondary hyperparathyroid-
ism [103]. Similar results were obtained after intermittent oral or
intraperitoneal calcitriol therapy in children and adolescents with
biopsy-proven osteitis fibrosa (Fig. 4) [25]; however, a substantial
proportion of pediatric patients given large intermittent doses of
calcitriol develop adynamic, or aplastic, lesions of renal osteodys-
trophy with subnormal bone formation after 8 to 12 months of
treatment [25]. In some patients, the development of adynamic
bone was associated with falling serum PTH and alkaline phos-
phatase levels. Others, however, had persistently high serum PTH
and alkaline phosphatase values despite marked decreases in
bone formation documented by repeat bone biopsy after 12
months of treatment. Indeed, some patients with normal bone
formation rates had serum PTFI values that remained above 500
pg/ml as measured by the immunoradiometric assay for intact
PTH, levels almost invariably associated with bone biopsy evi-
dence of secondary hyperparathyroidism in untreated patients or
in those receiving daily doses of oral calcitriol [33, 94].
Such findings suggest that the skeletal response to intermittent
calcitriol therapy in children differs substantially from that previ-
ously documented during treatment with daily oral doses of
1,25-dihydroxyvitamin D [97]. Moreover, a portion of the suppres-
sive action of calcitriol on osteoblasts appears to be independent
of vitamin D-induced changes in the serum level of PTI-I during
intermittent calcitriol therapy [104, 105]. Whether decreases in
chondrocyte activity in growth plate cartilage also occur during
high dose, intermittent calcitriol therapy remains to be deter-
mined, but the potential for calcitriol-induced changes in epiph-
yseal growth warrants further evaluation. The role of altered GH
1-
Table 1. Three patients with stable chronic renal failure receiving daily
doses of oral calcitriol
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Fig. 4. Bone formation before and after 12 months of intermittent calcitriol
therapy in patients with secondaty hypeiparathyroidism. (From [25]; used
with permission.)
and IGF-I metabolism as potential modifiers of the suppressive
actions of 1,25-dihydroxyvitamin D on bone and cartilage remains
uncertain.
Although linear growth was not assessed, the relatively high
incidence of the adynamic lesion of renal osteodystrophy after
intermittent calcitriol therapy is striking [25]. Little is known
about the long-term consequences of adynamic bone either in
adults or in children, and the disorder may simply represent a
state of relative hypoparathyroidism in some patients. Adverse
effects that may arise due to diminished skeletal remodeling
include poor fracture healing and delays in microfracture repair in
cancellous bone. One preliminary report suggested that avascular
necrosis was more common after renal transplantation in patients
with subnormal rates of bone formation and turnover before
surgery [106]. The frequency of skeletal fractures may also be
higher in adult dialysis patients with adynamic bone than in those
with other forms of renal osteodystrophy [107], In the developing
skeleton, reductions in peak bone mass and impaired longitudinal
growth are matters of concern, but data that address these issues
are currently not available.
Because of these concerns and until sufficient information on
linear growth becomes available, it may be prudent to avoid
inducing adynamic lesions of bone by intense vitamin D therapy in
children who have yet to reach skeletal maturity, and it has been
suggested that vitamin D therapy should be withheld in patients
with the adynamic lesion [40, 93]. This recommendation is prob-
lematic, however, since calcitriol therapy may be necessary for
normal skeletal development in children with renal disease [22].
Indeed, it is not known whether the concurrent administration of
1,25-dihydroxyvitamin D is required during growth hormone
therapy since virtually all pediatric patients treated with recombi-
nant human growth hormone (rhGH) have also received calcit-
riol, Additional studies should determine whether 1,25-dihy-
droxyvitamin D enhances or attenuates the rise in linear growth
induced by rhGH therapy in pre-pubertal children and whether
the interactions between calcitriol and rhGH at the tissue and
cellular levels in cancellous bone and growth plate cartilage are
similar or different.
Previous studies of growth hormone therapy in children with
chronic renal failure have failed to consider the role of pre-
existing bone disease or concurrent treatment with calcitriol as
modifiers of the therapeutic response to rhGH. Until these
important issues are further clarified, the full impact of rhGH
therapy on linear growth in pediatric patients with various forms
of renal osteodystrophy remains uncertain. Guidelines for the
proper use of this valuable, but expensive, therapeutic agent must
be developed, and the potential interaction between calcitriol and
rhGH therapy must be further examined to determine the optimal
utilization of these two potent therapeutic agents in children with
chronic renal disease.
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